ArticleCell2024
The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity.
Abstract read
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Inhibition by ATP regulates the activity of a CBASS anti-phage nucleotide cyclase.The Biochemical journal · 2026Article
- Prokaryotic Schlafen proteins cleave tRNAs during type III CRISPR immunity.Nature communications · 2026Article
- Potential role of a CRISPR-Cas-activated toxin-antitoxin system in bacterial immunity.Nature communications · 2026Article
- Predicting an intrinsic conformational twist in Card1: an in silico study.Journal of molecular modeling · 2026Article
- The CRISPR ring nuclease Csx15 oligomerises on cyclic nucleotide binding to regulate antiviral defence.The Biochemical journal · 2026Article
- Mechanistic basis for selective Csm6-2 activation by cyclic penta-adenylate in a type III CRISPR-Cas system.The EMBO journal · 2026Article
- Structural and functional insights into the adenosine deaminase of the type III-B CRISPR-Cas system.Nucleic acids research · 2026Article
- Structural plasticity enables broad cAn binding and dual activation of CRISPR-associated ribonuclease Cdn1.Nucleic acids research · 2026Article
- Manipulation of the nucleotide pool in human, bacterial and plant immunity.Nature reviews. Immunology · 2026Review
- The twist-and-squeeze activation of CARF-fused adenosine deaminase by cyclic oligoadenylates.The EMBO journal · 2025Article
- CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR-Cas response.Nucleic acids research · 2025Article
- Cap1 forms a cyclic tetra-adenylate-induced membrane pore during the type III-A CRISPR-Cas immune response.bioRxiv : the preprint server for biology · 2025Article
- Structural and functional relevance of the DUF4352 domain in antiviral immunity and physiology of mycobacteria.Nucleic acids research · 2025Article
- Molecular mechanisms of CBASS phospholipase effector CapV mediated membrane disruption.Nature communications · 2025Article
- Cat1 forms filament networks to degrade NADScience (New York, N.Y.) · 2025Article
- m6A modification is incorporated into bacterial mRNA without specific functional benefit.Nucleic acids research · 2025Article
- Nucleic acid recognition during prokaryotic immunity.Molecular cell · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Christian F BacaLaboratory of Bacteriology, The Rockefeller University, New York, NY 10065, USA; Tri-Institutional PhD Program in Chemical Biology, Weill Cornell Medical College, Rockefeller University and Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Puja MajumderStructural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
James H HicklingLaboratory of Bacteriology, The Rockefeller University, New York, NY 10065, USA.
Linzhi YeTri-Institutional PhD Program in Chemical Biology, Weill Cornell Medical College, Rockefeller University and Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, NY 10065, USA.
Marianna TeplovaStructural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Sean F BradyLaboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, NY 10065, USA.
Dinshaw J PatelStructural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address: pateld@mskcc.org.
Luciano A MarraffiniLaboratory of Bacteriology, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA. Electronic address: marraffini@rockefeller.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9MX-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Sean McSweeney · 2019 to 2026
$38.6MDiscovery of Antibiotics from Soil Microbiomes Using MetagenomicsR35GM122559 · NIGMS · ROCKEFELLER UNIVERSITY · PI SEAN F BRADY · 2017 to 2026
$4.7MTri-Institutional PhD Program in Chemical BiologyT32GM136640 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEREK S TAN · 2020 to 2026
$2.4MDevelopment of small molecule cGAS inhibitors for repression of dsDNA-triggered interferon expressionR01AI141507 · NIAID · ROCKEFELLER UNIVERSITY · PI TUSCHL, THOMAS · 2019 to 2022
$2.1MSpacer acquisition during the type III-A CRISPR-Cas immune responseR01GM149834 · NIGMS · ROCKEFELLER UNIVERSITY · PI Luciano A Marraffini · 2023 to 2026
$1.7M'Class I and III Multi-subunit CRISPR-Cas Surveillance Complexes: Recognition, Cleavage, Autoimmunity and Inhibition’R01GM129430 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PATEL, DINSHAW J · 2019 to 2022
$1.4MStructure-Activity Based Mechanistic Insights into Cleavage Chemistry by Self-Cleaving Nucleolytic RibozymesR01GM145888 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PATEL, DINSHAW J · 2022 to 2025
$1.3MNCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI141507NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R01 GM129430NIGMS NIH HHS R01 GM145888NIGMS NIH HHS R01 GM149834NIGMS NIH HHS R35 GM122559NIGMS NIH HHS T32 GM136640NIGMS NIH HHS U24 GM129539
Abstract
Type III CRISPR systems provide immunity against genetic invaders through the production of cyclic oligo-adenylate (cA
Indexed as
Adenosine DeaminaseAdenosine TriphosphateCRISPR-Cas SystemsAdenine NucleotidesCryoelectron MicroscopyModels, MolecularProtein DomainsAdenine NucleotidesAdenosine DeaminaseAdenosine Triphosphateabortive infectionadenosine deaminaseanti-phage defensebacteriophageCARFCRISPRcryo-EMcyclic oligoadenylatedeaminationX-ray crystallography
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.